“Bernstein Upgrades Gilead; Contained Medicaid Risk Ensures Outperform”
Gilead Sciences retains its Outperform rating from Bernstein SocGen Group, despite recent Medicaid pricing changes. Thanks to Gilead's limited exposure to these changes, its financial impact is predicted to be minimal, ensuring the company's continuous growth and innovative research in the biopharmaceutical industry. Read more
Read More“Gilead Secures Bernstein’s Outperform, Medicaid Risk Contained”
Bernstein SocGen Group maintains a positive Outperform rating on Gilead Sciences, asserting limited financial risk amid Medicaid pricing changes. Primarily affecting Genvoya and Odefsey drugs, which represent a minority portion of their portfolio, Gilead's revenue stability shows resilience to these adjustments, instilling investor assurance. Read more
Read More
“H.C. Wainwright Holds Neutral View on Biohaven Following BHV-7000 Hiccup”
Biohaven's disappointing clinical trial results for depression drug BHV-7000 reaffirm the firm's neutral rating by H.C Wainwright. As BHV-7000 fails to hit primary and secondary endpoints, it highlights the volatile nature of pharma R&D. Despite setbacks, Biohaven's potential in immunology, obesity, and epilepsy research remains promising. Read more
Read More